We’re proud to announce that Velocity is a founding member of the newly launched Association of MultiSite Research Corporations (AMRC)! This innovative trade association unites 14 leading organizations to address the systemic challenges in clinical trials and drive meaningful change across the industry.
With over 80 fully integrated research sites across the U.S. and Europe and a network of more than 1.5M participants, Velocity is committed to patient-centric care, superior recruitment, and reliable data collection to accelerate the development of new drugs, medical devices, and diagnostics.
We are also honored to share that our President and CEO, Paul Evans, will serve as the Vice Chairman of AMRC, championing its mission to improve efficiency, inclusivity, and outcomes in clinical research.
Why change is needed:
- The number of drugs in development has nearly doubled in the past decade, growing from 3,200 in 2012 to over 6,100 in 2022, increasing trial complexity.
- Recruitment rates per site have declined by 14% in oncology and 54% in non-oncology trials, making patient enrollment more challenging.
- Rising inefficiencies delay critical therapies, with each day of delay costing sponsors an estimated $540,000 in lost revenue.
